MES upgrade tactic: Slay the tweak dragon

Process data are becoming as important as the product itself in drug manufacturing, says the lead engineer on a multi-site implementation of a manufacturing execution system--no process documentation, no product release. So Hoffmann-La Roche is automating across eight sites using the Rockwell Automation MES Core.

Batch data-collection methods pale in comparison to those of an MES, reflecting the current regulatory expectation for mastery of not just process but also process measurement. There's a corporate mandate, too, for greater global operational consistency. The means for serving both masters are centralized best practices and error reduction--all for the end of "significant cost savings," says Robert Fretz in a trade magazine interview.

Fretz, who heads up the MES program as part of Roche's Pharma Global Engineering group, says the centralized approach lets him collect experiences and best practices from all sites into one system, for the benefit of all. It also aligns business processes to uniform compliance and efficiency standards.

One of his key implementation tactics is to keep customization to a minimum. "Although we are challenged to reach less than 10% customizations by the different type of site operations (solids, parenterals, packaging), having too many customizations will lead to being stuck with an older version [of the MES] as costs for upgrades are getting prohibitively high," says Fretz.

- read the interview

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.